# Intraoperative Confocal Laser Endomicroscopy Detects Prostate Cancer at the Single-Cell Level with High Specificity and in Real Time: A Preclinical Proof of Concept

**Authors:** Ann-Christin Eder, Jessica Matthias, Francois Lacombe, Lisa-Charlotte Domogalla, Antoine Jacques, Nils Steinacker, Gaetan Christien, Elodie Martin, Aline Criton, Matthias Eder

PMC · DOI: 10.3390/ph18060841 · Pharmaceuticals · 2025-06-04

## TL;DR

This study shows that a new imaging technique can detect prostate cancer cells in real time during surgery, improving precision.

## Contribution

The novel use of PSMA-targeting molecules with confocal laser endomicroscopy for real-time, single-cell prostate cancer detection is demonstrated.

## Key findings

- NIR-pCLE detected PSMA-specific fluorescence at concentrations above 30 nM in vitro.
- Optimal PSMA-914 dosing of 5 nmol enabled cellular resolution imaging in LNCaP xenografts.
- PET/MRI confirmed high tumor uptake and favorable distribution of PSMA-914.

## Abstract

In prostate cancer (PCa) surgery, precise tumor margin identification remains challenging despite advances in surgical techniques. This study evaluates the combination of tumor-specific near-infrared imaging with the PSMA-targeting molecule PSMA-914 and optical endomicroscopy (NIR-pCLE) for single-cell-level tumor identification in a preclinical proof of concept. Methods: NIR-pCLE imaging of varying PSMA-914 concentrations was performed on PSMA-positive LNCaP and PSMA-negative PC-3 cells using Cellvizio® 100 with pCLE Confocal Miniprobes™. To identify optimal PSMA-914 dosing for in vivo imaging, different doses (0–10 nmol) were evaluated using NIR-pCLE, Odyssey CLx imaging, and confocal microscopy in an LNCaP tumor-bearing xenograft model. A proof of concept mimicking a clinical workflow was performed using 5 nmol [68Ga]Ga-PSMA-914 in LNCaP and PC-3 tumor xenografts, including PET/MRI, in/ex vivo NIR-pCLE imaging, and microscopic/macroscopic imaging. Results: NIR-pCLE detected PSMA-specific fluorescence at concentrations above 30 nM in vitro. The optimal dose was identified as 5 nmol PSMA-914 for NIR-pCLE imaging with cellular resolution in LNCaP xenografts. PET/MRI confirmed high tumor uptake and a favorable distribution profile of PSMA-914. NIR-pCLE imaging enabled real-time, single-cell-level detection of PSMA-positive tissue, visualizing tumor heterogeneity, confirmed by ex vivo microscopy and imaging. Conclusions: This preclinical proof of concept demonstrates the potential of intraoperative PSMA-specific NIR-pCLE imaging to visualize tissue structures in real time at cellular resolution. Clinical implementation could provide surgeons with valuable additional information, potentially advancing PCa patient care through improved surgical precision.

## Linked entities

- **Proteins:** FOLH1 (folate hydrolase 1)
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** FOLH1 (folate hydrolase 1) [NCBI Gene 2346] {aka FGCP, FOLH, GCP2, GCPII, NAALAD1, PSM}
- **Diseases:** tumor (MESH:D009369), PCa (MESH:D011471)
- **Chemicals:** pCLE (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** LNCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0395), PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), Cellvizio  100 — Equus caballus (Horse), Transformed cell line (CVCL_C4M8)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12196187/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12196187/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12196187/full.md

---
Source: https://tomesphere.com/paper/PMC12196187